Insiders trading at Beam Therapeutics
Over the last 5 years, insiders at Beam Therapeutics have traded over $63,012,019 worth of Beam Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Llc Fmr y Kristina Burow. On average, Beam Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $1,019,987. The most recent stock trade was executed by Amy Simon on 1 July 2024, trading 1,250 units of BEAM stock currently worth $29,100.
What does Beam Therapeutics do?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
What does Beam Therapeutics's logo look like?
Beam Therapeutics executives and stock owners
Beam Therapeutics executives and other stock owners filed with the SEC include:
-
Terry-Ann Burrell,
Chief Financial Officer, Treasurer -
John Evans,
Chief Executive Officer, Director -
Giuseppe Ciaramella,
President, Chief Scientific Officer -
John M. Evans M.B.A.,
CEO & Director -
Dr. Giuseppe Ciaramella Ph.D.,
Pres & Chief Scientific Officer -
Terry-Ann Burrell M.B.A.,
CFO & Treasurer -
Carole Ho,
Independent Director -
Mark Fishman,
Independent Director -
Graham Cooper,
Independent Director -
Robert Nelsen,
Independent Director -
Stephen Knight,
Independent Director -
Kristina Burow,
Independent Director -
Christine Swenson,
Senior Vice President - Regulatory Affairs -
Manmohan Singh,
Senior Vice President - Pharmaceutical Sciences and Delivery Technology -
David Liu,
Co-Founder -
J. Keith Joung,
Co-Founder -
Dr. Alexis Komor Ph.D.,
Co-Founder -
Dr. Nicole Gaudelli Ph.D.,
Co-Founder -
Suzanne Fleming,
Chief Accounting Officer -
Dr. J. Keith Joung M.D., Ph.D.,
Co-Founder -
Courtney Wallace,
Chief Bus. Officer -
Susan O'Connor,
Chief HR Officer -
Dr. Christine P. Bellon J.D., Ph.D.,
Sr. VP, Chief Legal Officer & Corp. Sec. -
Brian Riley,
Sr. VP of Technical Operations -
Dr. Feng Zhang,
Co-Founder -
John Maraganore,
-
Kathleen E Walsh,
-
Bethany J Cavanagh,
SVP, Finance and Treasurer -
Group, Llc Green Jeremy Red...,
-
Venture Partners Ix, Llcarc...,
-
Venture Partners Ix, Llcarc...,
-
Llc Fmr,
-
Amy Simon,
Chief Medical Officer -
Christine Bellon,
Chief Legal Officer -
Christi Shaw,